Abstract
Visual disorder is one of the non-motor symptoms found in Parkinson’s disease (PD). It can be easily identified in the early stages even before the spread of pathological conditions to the brain parts. Studies have revealed that loss of dopamine (DA) cells in retinal layers is a prime cause for both retinal disturbance and pathological conditions of PD. This reduction of DA in retina is due to the aggregation of phosphorylated α-synuclein (aSyn) in the intra-retinal region, which eventually results in visual impairment in PD. Until now, very limited studies have been focused on the mechanism of aSyn influence and DA depletion as a cause for both retinal layer dysfunction and PD. Thus, more research is warranted to provide the missing connection between the exact role of DA and aSyn as a risk factor for visual problems in PD. Hence, the current review’s focus is on the function and effects of DA degeneration in retinal cells of PD. Further, we suggest that iron plays a major role in regulating the aggregation of aSyn in the DA cells of retina and brain in PD. The study finds that the unidentified pathophysiological role of retinal degeneration in PD is an essential biomarker that needs further investigation to use it as a novel therapy in treating retinal dysfunctions in PD.
Similar content being viewed by others
Abbreviations
- PD:
-
Parkinson’s disease
- AD:
-
Alzhiemer’s disease
- DA:
-
Dopaminergic neurons
- aSYN:
-
α-Synuclein
- OCT:
-
Optical coherence tomography
- mfERG:
-
Multifocal ERG
- ERG:
-
Electroretinograms
- VEP:
-
Visual-evoked potentials
- TH:
-
Tyrosine hydroxylase
- MPTP:
-
1-Methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine
- PERG:
-
Pattern electroretinogram
- STF:
-
Spatial tuning function
- RNFL:
-
Retinal nerve fiber layer
- RPE:
-
Retinal epithelial cells
- IPL:
-
Inner plexiform layer
- INL:
-
Inner nuclear layer
- GCL:
-
Ganglion cell layer
- PL:
-
Photoreceptor layer
- GPCR:
-
G-protein coupled receptor protein
- cAMP:
-
Cycline adenosine monophosphate
- DAT:
-
Dopamine transporter
- LTS:
-
Lewy-type α-synucleinopathy
- DARC:
-
Detection of apoptosing retinal cells
- SD-OCT:
-
Spectral-domain optical coherence tomography
- VH:
-
Visual hallucination
References
Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinson’s disease. Brain 132:1128–1145
Bodis-Wollner I (2009) Retinopathy in Parkinson disease. J Neural Transm Suppl 116:1493–1501
Aydin TS, Umit D, Nur OM, Fatih U, Asena K, Nefse OY, Serpil Y (2018) Optical coherence tomography findings in Parkinson’s disease. Kaohsiung J Med Sci 34:166–171
Zhou Z, Chen T, Wang M, Jin L, Zhao Y, Chen S, Wang C, Zhang G, Wang Q, Deng Q, Liu Y, Morgan IG, He M, Liu Y, Congdon N (2017) Pilot study of a novel classroom designed to prevent myopia by increasing children’s exposure to outdoor light. PLoS One 12:e0181772
Djamgoz MB, Hankins MW, Hirano J, Archer SN (1997) Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 37:3509–3529
Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N (2018) Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Mov Disord 33:1315–1324
Mammadova N, Summers CM, Kokemuller RD, He Q, Ding S, Baron T, Yu C, Valentine RJ, Sakaguchi DS, Kanthasamy AG, Greenlee JJ (2019) Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease. Neurobiol Dis 121:1–6
Funke C, Schneider SA, Berg D, Kell DB (2013) Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Neurochem Int 62:637–652
Armstrong RA (2008) Visual signs and symptoms of Parkinson's disease. Clin Exp Optom 91:129–138
Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, Devick S, Cronin R, Adler CH (2015) Abnormal visual contrast acuity in Parkinson’s disease. J Parkinsons Dis 5:125–130
Oh YS, Kim JS, Chung SW, Song IU, Kim YD, Kim YI, Lee KS (2011) Color vision in Parkinson’s disease and essential tremor. Eur J Neurol 18:577–583
Diederich NJ, Raman R, Leurgans S, Goetz CG (2002) Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 59:1249–1252
Polo V, Satue M, Rodrigo MJ, Otin S, Alarcia R, Bambo MP, Fuertes MI, Larrosa JM, Pablo LE, Garcia-Martin E (2016) Visual dysfunction and its correlation with retinal changes in patients with Parkinson’s disease: an observational cross-sectional study. BMJ Open 6:e009658
Shibasaki H, Tsuji S, Kuroiwa Y (1979) Oculomotor abnormalities in Parkinson’s disease. Arch Neurol 36:360–364
Elmar HP, Reinhart J, Dorothée L, Johanna H, Albert CL, Wolfgang B, Jan K (2012) Eye movement impairments in Parkinson’s disease: possible role of extradopaminergic mechanisms. BMC Neurol 12:5
Manohar SG, Husain M (2015) Reduced pupillary reward sensitivity in Parkinson's disease. NPJ Parkinson’s Dis 1:15026
Armstrong RA (2015) Oculo-visual dysfunction in Parkinson’s disease. J Parkinsons Dis 5:715–726
Armstrong RA (2017) Visual dysfunction in Parkinson's disease. Int Rev Neurobiol 134:921–946
Veruki ML (1997) Dopaminergic neurons in the rat retina express dopamine D2/3 receptors. Eur J Neurosci 9:1096–1100
He S, Weiler R, Vaney DI (2000) Endogenous dopaminergic regulation of horizontal cell coupling in the mammalian retina. J Comp Neurol 418:33–40
Xia XB, Mills SL (2004) Gap junctional regulatory mechanisms in the AII amacrine cell of the rabbit retina. Vis Neurosci 21:791–805
Ribelayga C, Cao Y, Mangel SC (2008) The circadian clock in the retina controls rod-cone coupling. Neuron 59:790–801
Nguyen-Legros J (1988) Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson’s disease. Surg Radiol Anat 10:137–144
Cuenca N, Herrero MT, Angulo A, De Juan E, Martınez- Navarrete GC, Lopez S, Barcia C, Martín-Nieto J (2005) Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson’s disease. J Comp Neurol 493:261–273
Crawford TJ, Goodrich S, Henderson L, Kennard C (1989) Predictive responses in PD: manual keypresses and saccadic eye movements to regular stimulus events. J Neurol Neurosurg Psychiatry 52:1033–1042
Biehlmaier O, Alam M, Schmidt WJ (2007) A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem Int 50:189–195
Ahmad I, Zhao X, Parameswaran S, Destache CJ, Rodriguez-Sierra J, Thoreson WB, Ahmad H, Sorrentino J, Balasubramanian S (2015) Direct differentiation of adult ocular progenitors into striatal dopaminergic neurons. Int J Stem Cells 8:106
Stutz B, da Conceição FS, Santos LE, Cadilhe DV, Fleming RL, Acquarone M, Gardino PF, de Melo Reis RA, Dickson PW, Dunkley PR, Rehen S (2014) Murine dopaminergic Müller cells restore motor function in a model of Parkinson's disease. J Neurochem 128(6):829–840
Ghilardi F, Chung M, Bodis-Wollner E, Dvorzniak IM, Glover A, Onofrj M (1988) Systemic 1-methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 43(3):255–262
Bodis-Wollner I (1990) Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci 13(7):296–302
Tatton WG, Kwan MM, Verrier MC, Seniuk NA, Theriault E (1990) MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res 527(1):21–31
Dyer RS, Howell WE, MacPhail RC (1981) Dopamine depletion slows retinal transmission. Exp Neurol 71(2):326–340
Onofrj M, Bodis-Wollner I (1982) Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann Neurol 11(5):484–490
Febbraro F, Giorgi M, Caldarola S, Loreni F, Romero-Ramos M (2012) Alpha-synuclein expression is modulated at the translational level by iron. NeuroReport 23:576–580
Lu Y, Prudent M, Fauvet B, Lashuel HA, Girault HH (2011) Phosphorylation of alpha-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of alpha-synuclein in the pathogenesis of Parkinson’s disease and related disorders. ACS Chem Neurosci 2:667–675
Davies P, Moualla D, Brown DR (2011) Alpha-synuclein is a cellular ferrireductase. PLoS One 6:e15814
Paris I, Martinez-Alvarado P, Cardenas S, Perez-Pastene C, Graumann R, Fuentes P, Olea-Azar C, Caviedes P, Segura-Aguilar J (2005) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 18:415–419
Duce JA, Wong BX, Durham H, Devedjian JC, Smith DP, Devos D (2017) Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. Mol Neurodegener 12:45
Gallegos S, Pacheco C, Peters C, Opazo C, Aguayo LG (2015) Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson’s disease. Front Neurosci 9:1–11
Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurol 3:932–942
Lee JY, Ahn J, Kim TW, Jeon BS (2014) Optical coherence tomography in Parkinson's disease: is the retina a biomarker? J Parkinson's Dis 4:197–204
Bodis-Wollner I, Miri S, Glazman S (2014) Venturing into the no-man’s land of the retina in Parkinson’s disease. Mov Disord 29:15–22
Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N (2014) Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett 571:34–38
Surguchov A, McMahan B, Masliah E, Surgucheva I (2001) Synucleins in ocular tissues. J Neurosci Res 65:68–77
Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123:383–396
Veys L, Vandenabeele M, Ortuño-Lizarán I, Baekelandt V, Cuenca N, Moons L, De Groef L (2019) Retinal α-synuclein deposits in Parkinson’s disease patients and animal models. Acta Neuropathol 5:1–7
Martınez-Navarrete GC, Martın-Nieto J, Esteve RJ, Angulo A, Cuenca N (2007) Alpha synuclein gene expression profile in the retina of vertebrates. Mol Vis 13:949–961
Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S (2014) α-Synuclein in the inner retina in Parkinson disease. Ann Neurol 75:964–966
Le W, Dong J, Li S, Korczyn AD (2017) Can biomarkers help the early diagnosis of Parkinson’s disease? Neurosci Bull 33:535–542
Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR (2016) Visual dysfunction in Parkinson’s disease. Brain 139:2827–2843
Cuenca N, Fernandez-Sanchez L, Campello L, Maneu V, De la Villa P, Lax P, Pinilla I (2014) Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res 43:17–75
Miri S, Glazman S, Mylin L, Bodis-Wollner I (2016) A combination of retinal morphology and visual electrophysiology testing increases diagnostic yield in Parkinson’s disease. Parkinsonism Relat Disord 22:S134–S137
Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K (2015) Bioelectrical function and structural assessment of the retina in patients with early stages of Parkinson's disease (PD). Doc Ophthalmol 131:95–104
Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A (2004) Retinal nerve fiber layer thinning in Parkinson disease. Vis Res 44:2793–2797
Kirbas S, Turkyilmaz K, Tufekci A, Durmus M (2013) Retinal nerve fiber layer thickness in Parkinson disease. J Neuroophthalmol 33:62–65
La Morgia C, Barboni P, Rizzo G, Carbonelli M, Savini G, Scaglione C, Capellari S, Bonazza S, Giannoccaro MP, Calandra BG, Liguori R (2013) Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur J Neurol 20:198–201
Altintas O, Iseri P, Ozkan B, Caglar Y (2008) Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease. Doc Ophthalmol 116:137–146
Moreno-Ramos T, Benito-Le´on J, Villarejo A, Bermejo-Pareja F (2013) Retinal nerve fiber layer thinning in dementia associated with Parkinson’s disease, dementia with Lewy bodies, and Alzheimer’s disease. J Alzheimer’s Dis 34:659–694
Garcia-Martin E, Satue M, Otin S, Fuertes I, Alarcia R, Larrosa JM, Polo V, Pablo LE (2013) Retina measurements for diagnosis of Parkinson disease. Retina 34:971–980
Satue M, Garcia-Martin E, Fuertes I, Otin S, Alarcia R, Herrero R, Bambo MP, Pablo LE, Fernandez FJ (2013) Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson’s disease patients. Eye 27:507–514
Albrecht P, Muller AK, Sudmeyer M, Ferrea S, Ringelstein M, Cohn E, Aktas O, Dietlein T, Lappas A, Foerster A, Hartung HP, Schnitzler A, Methner A (2012) Optical coherence tomography in Parkinsonian syndromes. PLoS One 7:e34891
Cubo E, L´opez Pe˜na MJ, Diez-Feijo VE, P´erez GO, Garcia GP, Araus GE, Prieto TR, Mariscal PN, Armesto D (2014) Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease. J Neural Transm 121:139–145
Garcia-Martin E, Satue M, Fuertes I, Otin S, Alarcia R, Herrero R, Bambo MP, Fernandez J, Pablo LE (2012) Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson’s disease. Ophthalmology 119:2161–2167
Ma LJ, Xu LL, Mao CJ, Fu YT, Ji XY, Shen Y, Chen J, Yang YP, Liu CF (2018) progressive changes in the retinal structure of patients with Parkinson’s disease. J Parkinson's Dis 8:85–92
Satue M, Rodrigo MJ, Obis J, Vilades E, Gracia H, Otin S, Fuertes MI, Alarcia R, Crespo JA, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E (2017) Evaluation of progressive visual dysfunction and retinal degeneration in patients with Parkinson’s disease. Investig Ophthalmol Vis Sci 58:1151–1157
Garcia-Martin E, Larrosa JM, Polo V, Satue M, Marques ML, Alarcia R, Seral M, Fuertes I, Otin S, Pablo LE (2014) Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol 157:470–478
Schneider M, M¨uller HP, Lauda F, Tumani H, Ludolph AC, Kassubek J, Pinkhardt EH (2014) Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study. J Neural Transm 121:41–47
Schrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I (2012) Interocular asymmetry of foveal thickness in Parkinson’s disease. J Ophthalmol 2012:728457
Hajee ME, March WF, Lazzaro DR, Wolintz AH, Shrier EM, Glazman S, Bodis-Wollner IG (2009) Inner retinal layer thinning in Parkinson’s disease. Arch Ophthalmol 127:737–741
Adam CR, Shrier E, Ding Y, Glazman S, Bodis-Wollner I (2013) Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol 33:137–142
Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S (2010) Detection of retinal changes in Parkinson’s disease with spectral-domain optical coherence tomography. Clin Ophthalmol 4:1427–1432
Normando EM, Davis BM, De Groef L, Nizari S, Turner LA, Ravindran N, Pahlitzsch M, Brenton J, Malaguarnera G, Guo L, Somavarapu S (2016) The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun 4:86
Cordeiro MF, Guo L, Coxon KM, Duggan J, Nizari S, Normando EM, Sensi SL, Sillito AM, Fitzke FW, Salt TE, Moss SE (2010) Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis 1:e3
Kwapong WR, Ye H, Peng C, Zhuang X, Wang J, Shen M, Lu F (2018) Retinal microvascular impairment in the early stages of Parkinson's disease. Investig Ophthalmol Vis Sci 59:4115–4122
Chorostecki J, Seraji-Bozorgzad N, Shah A, Bao F, Bao G, George E, Gorden V, Caon C, Frohman E, Bhatti MT, Khan O (2015) Characterization of retinal architecture in Parkinson's disease. J Neurol Sci 355:44–48
Garcia-Martin E, Rodriguez-Mena D, Satue M, Almarcegui C, Dolz I, Alarcia R, Seral M, Polo V, Larrosa JM, Pablo LE (2014) Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity. Investig Ophthalmol Vis Sci 55:696–705
Veselá O, Růžička E, Jech R, Roth J, Štěpánková K, Mečíř P, Solano Z, Preclíková E (2001) Colour discrimination impairment is not a reliable early marker of Parkinson's disease. J Neurol 248:975–978
Sun L, Zhang H, Gu ZQ, Cao M, Li DW, Chan P (2014) Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson’s disease. Eur J Med Res 19:29
Acknowledgement
I thank Sankara Nethralaya, Chennai, Avinashilingam Institute for Home Science and Higher Education for Women, and Bharathiar University, Coimbatore, for providing the necessary help to carry out the article review process.
Funding
No funding was obtained to carry out this review article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
SMD, IM, APN, DV and VB declare that they have no conflict of interest.
Research involving human participants and/or animals
This is a review article; thus, it does not contain any studies with human participants performed by any of the authors.
Informed consent
This is a review article; thus it does not need any consent form.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mohana Devi, S., Mahalaxmi, I., Aswathy, N.P. et al. Does retina play a role in Parkinson's Disease?. Acta Neurol Belg 120, 257–265 (2020). https://doi.org/10.1007/s13760-020-01274-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-020-01274-w